2010-01-07
Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Publication
Publication
Vooruitgang in de behandeling van lokaal gevorderd en gemetastaseerd niet-kleincellig longcarcinoom
Lung cancer is the leading cause of cancer mortality in the United States and Europe. Approximately 85% of the patients with lung cancer have non–small cell lung cancer (NSCLC), which can be classified into squamous, adeno, large cell and not otherwise specified (NOS) histologies. The most common histologies are: adenocarcinoma ( 50%), squamous cell ( 20%), and large cell ( 10%). More than two third of the patients have locally advanced or metastatic disease at the time of diagnosis.
| Additional Metadata | |
|---|---|
| , | |
| Merck NV/SA Belgium, GSK, Mundipharma, MSD, Pierre Fabre Médicament Bénélux, Boehringer-Ingelheim | |
| H.C. Hoogsteden (Henk) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/17725 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Surmont, V. (2010, January 7). Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer. Retrieved from http://hdl.handle.net/1765/17725 |
|
